What's up…and what's not
What's up… and what's not
Selenium for prostate cancer prevention
Selenium, a mineral with antioxidant properties, became a cancer prevention candidate in the mid-1990s after a secondary analysis of results from a skin cancer prevention study found that the men assigned to take selenium pills had 63% fewer cases of prostate cancer than men in the placebo group.
Optimism about antioxidants was running high. Other studies also indicated that the mineral might protect the prostate. And at a cost of about a nickel a day, or less than $20 a year, selenium would be an incredible bargain even if the risk reduction was modest. There had also been some results suggesting that vitamin E might protect against prostate cancer. So in 2001, the National Cancer Institute (NCI) launched the Selenium and Vitamin E Cancer Prevention Trial, or SELECT. A total of 35,000 men were enrolled and randomly assigned to take selenium (200 micrograms daily), vitamin E (400 international units), both, or placebo pills. We'd have to wait awhile — final results weren't expected till 2013 — but SELECT was supposed to be the last word on selenium.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.